Nanoscope Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
8
Active:2
Completed:4
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Recruiting
- Conditions
- Macular DegenerationGeographic AtrophyStargardt Disease
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06805474
- Locations
- 🇺🇸
Retina of North Texas,, Dallas, Texas, United States
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Active, not recruiting
- Conditions
- RetinitisRetinitis PigmentosaRetinal DiseasesEye Diseases, HereditaryRetinal DystrophiesRetinal DegenerationEye Diseases
- Interventions
- Biological: Gene Therapy product-MCO-010
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06162585
- Locations
- 🇵🇷
Nanoscope Clinical Site, Arecibo, Puerto Rico
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Active, not recruiting
- Conditions
- Stargardt Disease
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06048185
- Locations
- 🇺🇸
Nanocope Clnical Site, Miami, Florida, United States
🇺🇸Nanoscope Clinical Site, McAllen, Texas, United States
A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection
- Conditions
- Retinal DiseaseRetinitis PigmentosaRetinal Degeneration
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05921162
- Locations
- 🇮🇳
JPM Rotary Club of Cuttack Eye Hospital and Research Institute, Cuttack, Odisha, India
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
Completed
- Conditions
- Retinitis PigmentosaRetinal Dystrophy
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05820100
- Locations
- 🇵🇷
Nanoscope Clinical Site, Arecibo, Puerto Rico
🇺🇸Nanoscope Clincal Site, San Antonio, Texas, United States
- Prev
- 1
- 2
- Next
News
No news found